Acute myelogenous leukemia
Drug research and approvals for acute myelogenous leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 607 studies of acute myelogenous leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 23 drug trials for it since 2013, and FDA has 4 approved and 18 open orphan designations naming it.
- Recruiting worldwide: 607
- Trials authorized in Canada: 23
- FDA orphan approvals: 4
- EU medicines: 0
Recruiting Now
Newest start dates first, of 607 recruiting on ClinicalTrials.gov ↗- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for…NCT06930352 · Phase 2 · Uma Borate · starts Jan 15, 2027
- A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute…NCT07616921 · Not applicable · University of Washington · starts Dec 1, 2026
- FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaNCT07645469 · Phase 1 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSNCT07617363 · Phase 1 · Washington University School of Medicine · starts Nov 30, 2026
- Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT07783100 · Phase 2 · The First Affiliated Hospital of Xiamen University · starts Nov 11, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic…NCT07582172 · Phase 2 · City of Hope Medical Center · starts Nov 5, 2026
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML)…NCT07925190 · Phase 3 · Beijing InnoCare Pharma Tech Co., Ltd. · starts Nov 3, 2026
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxNCT07471841 · Phase 2 · Timothy Pardee · starts Nov 1, 2026
Trials Authorized in Canada
The 10 newest of 23; search them all in Canada trials| Apr 24, 2023 | A phase 1/2 first in human study of the menin-mll (kmt2a) inhibitor ko 539 in patients with relapsed or refractory acute myeloid leukemiaZIFTOMENIB (KO-539) | Kura Oncology | Ongoing |
| Aug 26, 2021 | A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of entospletinib in combination with intensive induction and…ENTOSPLETINIB (GS-9973) | KRONOS BIO, INC. | Ongoing |
| May 7, 2018 | A phase 3, randomized, controlled, open-label, clinical study of pevonedistat plus azacitidine versus single-agent azacitidine as first-line treatment for…PEVONEDISTAT (MLN4924) / AZACITIDINE | Takeda Pharmaceuticals USA | Ongoing |
| Aug 9, 2017 | A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ag-120 in combination with azacitidine in subjects ¿18 years of age with…IVOSIDENIB (AG-120) | Servier | Closed |
| Aug 16, 2016 | A phase I study of volasertib combined with standard induction chemotherapy for previously untreated patients with acute myeloid leukemia (viac)VOLASERTIB | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Pending |
| Jul 25, 2016 | A phase 1b/2 open-label, randomized study of 2 combinations of isocitrate dehydrogenase (idh) mutant targeted therapies plus azacitidine: oral ag-120 plus…ENASIDENIB (AG-221)/ IVOSIDENIB (AG-120) | Bristol-Myers Squibb | Closed |
| Mar 31, 2016 | A phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of ag-221 (cc-90007) versus conventional care regimens in older subjects…ENASIDENIB (AG-221)/ AZACITIDINE | Bristol-Myers Squibb | Ongoing |
| Feb 26, 2016 | A randomized multicenter, open-label, phase 2 study evaluating the efficacy and safety of azacitidine subcutaneous in combination with durvalumab (medi4736) in…VIDAZA (AZACITIDINE)/ DURVALUMAB | Bristol-Myers Squibb | Closed |
| Feb 8, 2016 | A phase 2, randomized, controlled, open-label, clinical study of the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in…PEVONEDISTAT / AZACITIDINE | Takeda Pharmaceuticals USA | Closed |
| Jan 7, 2016 | Phase I study of autologous acute myelogenous leukemia (aml) cells containing lentivirus engineering expression of il-12AUTOLOGOUS AML CELLS EXPRESSING IL-12 | UNIVERSITY HEALTH NETWORK | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 22| Aug 1, 2017 | IdhifaTreatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as… | Celgene Corporation | Approved |
| Sep 15, 1995 | LeukineFollowing induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to… | Immunex Corporation | Approved |
| Sep 27, 1990 | IdamycinTreatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia. | Adria Laboratories, Inc. | Approved |
| Dec 23, 1987 | NovantroneTreatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia. | Lederle Laboratories | Approved |
| Oct 17, 2025 | recombinant fusion protein composed of a high affinity MHC…treatment of acute myelogenous leukemia | Leukogene Therapeutics, Inc. | Designated |
| Nov 26, 2019 | Recombinant Bispecific antibody targeting CD123 and CD3Treatment of acute myelogenous leukemia | Aptevo Research and Development | Designated |
| Aug 21, 2019 | TalabostatTreatment of acute myelogenous leukemia | BioXcel Therapeutics, Inc. | Designated |
| Nov 25, 2014 | 225Ac-lintuzumabTreatment of acute myelogenous leukemia | Actinium Pharmaceuticals, Inc. | Designated |
| Mar 27, 2014 | LaromustineTreatment of acute myelogenous leukemia | NanoSHIFT LLC | Designated |
| Nov 19, 2012 | combretastatin A 1 diphosphateTreatment of acute myelogenous leukemia | Mateon Therapeutics, Inc. | Designated |
| Oct 31, 2012 | crenolanibTreatment of acute myelogenous leukemia | AROG Pharmaceuticals, LLC | Designated |
| Feb 4, 2011 | D-peptideTreatment of acute myelogenous leukemia | Immune System Key, Ltd | Designated |
| Feb 4, 2011 | MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)Treatment of acute myelogenous leukemia. | Takeda Development Center Americas, Inc. | Designated |
| Jun 24, 2010 | 1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoy…Treatment of acute myelogenous leukemia | Cyclacel Limited | Designated |
| Oct 21, 2004 | laromustineTreatment of acute myelogenous leukemia | Vion Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA